Literature DB >> 16384879

Cystic fibrosis: terminology and diagnostic algorithms.

K De Boeck1, M Wilschanski, C Castellani, C Taylor, H Cuppens, J Dodge, M Sinaasappel.   

Abstract

There is great heterogeneity in the clinical manifestations of cystic fibrosis (CF). Some patients may have all the classical manifestations of CF from infancy and have a relatively poor prognosis, while others have much milder or even atypical disease manifestations and still carry mutations on each of the CFTR genes. It is important to distinguish between these categories of patients. The European Diagnostic Working Group proposes the following terminology. Patients are diagnosed with classic or typical CF if they have one or more phenotypic characteristics and a sweat chloride concentration of >60 mmol/l. The vast majority of CF patients fall into this category. Usually one established mutation causing CF can be identified on each CFTR gene. Patients with classic CF can have exocrine pancreatic insufficiency or pancreatic sufficiency. The disease can have a severe course with rapid progression of symptoms or a milder course with very little deterioration over time. Patients with non-classic or atypical CF have a CF phenotype in at least one organ system and a normal (<30 mmol/l) or borderline (30-60 mmol/l) sweat chloride level. In these patients confirmation of the diagnosis of CF requires detection of one disease causing mutation on each CFTR gene or direct quantification of CFTR dysfunction by nasal potential difference measurement. Non-classic CF includes patients with multiorgan or single organ involvement. Most of these patients have exocrine pancreatic sufficiency and milder lung disease. Algorithms for a structured diagnostic process are proposed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16384879      PMCID: PMC2104676          DOI: 10.1136/thx.2005.043539

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  40 in total

1.  Cystic fibrosis: a 2002 update.

Authors:  David M Orenstein; Glenna B Winnie; Harold Altman
Journal:  J Pediatr       Date:  2002-02       Impact factor: 4.406

2.  Electrogenic ion transport in duodenum, an aid in cystic fibrosis diagnosis.

Authors:  K Hallberg; A Reims; B Strandvik
Journal:  Scand J Gastroenterol       Date:  2000-10       Impact factor: 2.423

Review 3.  Cystic fibrosis modifier genes.

Authors:  Jane Davies; Eric Alton; Uta Griesenbach
Journal:  J R Soc Med       Date:  2005       Impact factor: 5.344

4.  Recommendations for quality improvement in genetic testing for cystic fibrosis. European Concerted Action on Cystic Fibrosis.

Authors:  E Dequeker; H Cuppens; J Dodge; X Estivill; M Goossens; P F Pignatti; H Scheffer; M Schwartz; M Schwarz; B Tümmler; J J Cassiman
Journal:  Eur J Hum Genet       Date:  2000-09       Impact factor: 4.246

5.  Complete and rapid scanning of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by denaturing high-performance liquid chromatography (D-HPLC): major implications for genetic counselling.

Authors:  C Le Maréchal; M P Audrézet; I Quéré; O Raguénès; S Langonné; C Férec
Journal:  Hum Genet       Date:  2001-04       Impact factor: 4.132

6.  Nasal potential difference measurements in patients with atypical cystic fibrosis.

Authors:  M Wilschanski; H Famini; N Strauss-Liviatan; J Rivlin; H Blau; H Bibi; L Bentur; Y Yahav; H Springer; M R Kramer; A Klar; A Ilani; B Kerem; E Kerem
Journal:  Eur Respir J       Date:  2001-06       Impact factor: 16.671

7.  Genotype analysis and phenotypic manifestations of children with intermediate sweat chloride test results.

Authors:  P Desmarquest; D Feldmann; A Tamalat; M Boule; B Fauroux; G Tournier; A Clement
Journal:  Chest       Date:  2000-12       Impact factor: 9.410

8.  Lung disease associated with the IVS8 5T allele of the CFTR gene.

Authors:  P G Noone; C A Pue; Z Zhou; K J Friedman; E L Wakeling; M Ganeshananthan; R H Simon; L M Silverman; M R Knowles
Journal:  Am J Respir Crit Care Med       Date:  2000-11       Impact factor: 21.405

9.  Mutations of the cystic fibrosis gene and intermediate sweat chloride levels in children.

Authors:  Patrick Lebecque; Teresinha Leal; Christiane De Boeck; Martine Jaspers; Harry Cuppens; Jean-Jacques Cassiman
Journal:  Am J Respir Crit Care Med       Date:  2002-03-15       Impact factor: 21.405

10.  Variant cystic fibrosis phenotypes in the absence of CFTR mutations.

Authors:  Joshua D Groman; Michelle E Meyer; Robert W Wilmott; Pamela L Zeitlin; Garry R Cutting
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

View more
  64 in total

1.  Screening for the Most Common Mutations of CFTR Gene among Egyptian Children with Difficult-to-Treat Asthma.

Authors:  Mohammad Al-Haggar; Engy Osman; Abdel-Rahman Eid; Tarek Barakat; Samar El-Morsi
Journal:  J Pediatr Genet       Date:  2020-02-03

2.  Diagnosing CF: sweat, blood and years.

Authors:  J S Elborn; J M Bradley
Journal:  Thorax       Date:  2006-07       Impact factor: 9.139

3.  Sweat testing in CF.

Authors:  Lutz Naehrlich
Journal:  Thorax       Date:  2007-05       Impact factor: 9.139

4.  Diagnostic greed: using pictures to highlight diagnostic errors.

Authors:  Hangwi Tang
Journal:  Postgrad Med J       Date:  2007-03       Impact factor: 2.401

5.  Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders--updated European recommendations.

Authors:  Els Dequeker; Manfred Stuhrmann; Michael A Morris; Teresa Casals; Carlo Castellani; Mireille Claustres; Harry Cuppens; Marie des Georges; Claude Ferec; Milan Macek; Pier-Franco Pignatti; Hans Scheffer; Marianne Schwartz; Michal Witt; Martin Schwarz; Emmanuelle Girodon
Journal:  Eur J Hum Genet       Date:  2008-08-06       Impact factor: 4.246

6.  Molecular testing for cystic fibrosis carrier status practice guidelines: recommendations of the National Society of Genetic Counselors.

Authors:  Elinor Langfelder-Schwind; Barbara Karczeski; Michelle N Strecker; Joy Redman; Elaine A Sugarman; Christina Zaleski; Trisha Brown; Steven Keiles; Amy Powers; Sumheda Ghate; Rebecca Darrah
Journal:  J Genet Couns       Date:  2013-09-07       Impact factor: 2.537

7.  The influence of sex, gestational age, birth weight, blood transfusion, and timing of the heel prick on the pancreatitis-associated protein concentration in newborn screening for cystic fibrosis.

Authors:  Annette M M Vernooij-van Langen; J Gerard Loeber; Bert Elvers; Ralf H Triepels; Jos Roefs; Johan J Gille; Sandra Reijntjens; Edward Dompeling; Jeannette E Dankert-Roelse
Journal:  J Inherit Metab Dis       Date:  2012-06-28       Impact factor: 4.982

Review 8.  Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Authors:  C Castellani; H Cuppens; M Macek; J J Cassiman; E Kerem; P Durie; E Tullis; B M Assael; C Bombieri; A Brown; T Casals; M Claustres; G R Cutting; E Dequeker; J Dodge; I Doull; P Farrell; C Ferec; E Girodon; M Johannesson; B Kerem; M Knowles; A Munck; P F Pignatti; D Radojkovic; P Rizzotti; M Schwarz; M Stuhrmann; M Tzetis; J Zielenski; J S Elborn
Journal:  J Cyst Fibros       Date:  2008-05       Impact factor: 5.482

Review 9.  Atypical cystic fibrosis: identification in the primary care setting.

Authors:  Carrie A Schram
Journal:  Can Fam Physician       Date:  2012-12       Impact factor: 3.275

10.  Defining a mutational panel and predicting the prevalence of cystic fibrosis in oman.

Authors:  Uwe W Fass; Majid Al-Salmani; Said Bendahhou; Ganji Shivalingam; Catherine Norrish; Kallesh Hebal; Fiona Clark; Thomas Heming; Saleh Al-Khusaiby
Journal:  Sultan Qaboos Univ Med J       Date:  2014-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.